Logo image of NVAX

NOVAVAX INC (NVAX) Stock Price, Quote, News and Overview

NASDAQ:NVAX - Nasdaq - US6700024010 - Common Stock - Currency: USD

7.68  -0.06 (-0.78%)

After market: 7.7 +0.02 (+0.26%)

NVAX Quote, Performance and Key Statistics

NOVAVAX INC

NASDAQ:NVAX (5/20/2025, 8:21:47 PM)

After market: 7.7 +0.02 (+0.26%)

7.68

-0.06 (-0.78%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High23.86
52 Week Low5.01
Market Cap1.24B
Shares161.97M
Float147.81M
Yearly DividendN/A
Dividend YieldN/A
PE3.3
Fwd PE19.99
Earnings (Next)08-06 2025-08-06
IPO05-16 1973-05-16


NVAX short term performance overview.The bars show the price performance of NVAX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20

NVAX long term performance overview.The bars show the price performance of NVAX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of NVAX is 7.68 USD. In the past month the price increased by 22.88%. In the past year, price decreased by -50.45%.

NOVAVAX INC / NVAX Daily stock chart

NVAX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18 327.00B
AMGN AMGEN INC 13.25 147.86B
GILD GILEAD SCIENCES INC 14.1 135.84B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.96B
REGN REGENERON PHARMACEUTICALS 13.87 66.38B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.94B
ARGX ARGENX SE - ADR 98.52 35.31B
ONC BEIGENE LTD-ADR 5.89 25.53B
BNTX BIONTECH SE-ADR N/A 24.45B
NTRA NATERA INC N/A 21.01B
BIIB BIOGEN INC 8.25 19.13B
SMMT SUMMIT THERAPEUTICS INC N/A 18.11B

About NVAX

Company Profile

NVAX logo image Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company is headquartered in Gaithersburg, Maryland and currently employs 952 full-time employees. The firm offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. The company has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The firm is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Company Info

NOVAVAX INC

700 Quince Orchard Road

Gaithersburg MARYLAND 20878 US

CEO: Stanley C. Erck

Employees: 952

NVAX Company Website

NVAX Investor Relations

Phone: 12402682000

NOVAVAX INC / NVAX FAQ

What is the stock price of NOVAVAX INC today?

The current stock price of NVAX is 7.68 USD. The price decreased by -0.78% in the last trading session.


What is the ticker symbol for NOVAVAX INC stock?

The exchange symbol of NOVAVAX INC is NVAX and it is listed on the Nasdaq exchange.


On which exchange is NVAX stock listed?

NVAX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NOVAVAX INC stock?

13 analysts have analysed NVAX and the average price target is 17 USD. This implies a price increase of 121.35% is expected in the next year compared to the current price of 7.68. Check the NOVAVAX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NOVAVAX INC worth?

NOVAVAX INC (NVAX) has a market capitalization of 1.24B USD. This makes NVAX a Small Cap stock.


How many employees does NOVAVAX INC have?

NOVAVAX INC (NVAX) currently has 952 employees.


What are the support and resistance levels for NOVAVAX INC (NVAX) stock?

NOVAVAX INC (NVAX) has a support level at 6.08 and a resistance level at 7.69. Check the full technical report for a detailed analysis of NVAX support and resistance levels.


Is NOVAVAX INC (NVAX) expected to grow?

The Revenue of NOVAVAX INC (NVAX) is expected to grow by 36.71% in the next year. Check the estimates tab for more information on the NVAX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NOVAVAX INC (NVAX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NOVAVAX INC (NVAX) stock pay dividends?

NVAX does not pay a dividend.


When does NOVAVAX INC (NVAX) report earnings?

NOVAVAX INC (NVAX) will report earnings on 2025-08-06.


What is the Price/Earnings (PE) ratio of NOVAVAX INC (NVAX)?

The PE ratio for NOVAVAX INC (NVAX) is 3.3. This is based on the reported non-GAAP earnings per share of 2.33 and the current share price of 7.68 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVAX.


What is the Short Interest ratio of NOVAVAX INC (NVAX) stock?

The outstanding short interest for NOVAVAX INC (NVAX) is 28.64% of its float. Check the ownership tab for more information on the NVAX short interest.


NVAX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to NVAX. When comparing the yearly performance of all stocks, NVAX is a bad performer in the overall market: 85.99% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NVAX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to NVAX. While NVAX is still in line with the averages on profitability rating, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVAX Financial Highlights

Over the last trailing twelve months NVAX reported a non-GAAP Earnings per Share(EPS) of 2.33. The EPS increased by 173.5% compared to the year before.


Industry RankSector Rank
PM (TTM) 38.14%
ROA 37.02%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%379.05%
Sales Q2Q%610.3%
EPS 1Y (TTM)173.5%
Revenue 1Y (TTM)25.92%

NVAX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to NVAX. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 251.87% and a revenue growth 36.71% for NVAX


Ownership
Inst Owners60.5%
Ins Owners0.35%
Short Float %28.64%
Short Ratio6.45
Analysts
Analysts78.46
Price Target17 (121.35%)
EPS Next Y251.87%
Revenue Next Year36.71%